Search clinical trials for: gp160 Vaccine (MicroGeneSys)

Total 6212 results

National Institute of Allergy and Infectious Diseases...

Completed

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; MicroGeneSys Inc (nka Protein Sciences Corporation)

Completed

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

HIV Infections

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
International AIDS Vaccine Initiative
GlaxoSmithKline; George Washington University; Amsterdam UMC, location VUmc; Rockefeller...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

HIV Infections

United States, Netherlands
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

HIV Infections

United States
University of Maryland, Baltimore
Bill and Melinda Gates Foundation; Auro Vaccines LLC

Completed

A Safety and Immunogenicity Trial of IHV01 (FLSC-001)

HIV Infection

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
Marcus Altfeld, M.D., Ph.D.
GlaxoSmithKline

Completed

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines and Diagnostics, Inc

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
Roswell Park Cancer Institute

Terminated

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

HIV Infections

United States, South Africa
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults (HVTN 097)

HIV Infection

South Africa
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Prostate Cancer

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission

Breast Cancer
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
Medical University of South Carolina

Completed

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Aging | HIV Lipodystrophy

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States

3

Subscribe